QUESTIONS
Frequently Asked Questions
Short answers, with the citation attached where the answer rests on a number.
Does BPC-157 work immediately?
No controlled human evidence establishes an immediate effect or a reliable timeline. Community users describe changes over varying periods, but that is anecdotal, not clinical evidence, and it cannot establish onset. The published record is mostly animal work, and a recent review found only a few small human pilot studies with no rigorous large trial [2]. A mechanism that looks fast in a cell or rodent model does not supply a human timetable.
What does BPC-157 do in the body?
In animal models it accelerates repair of injured tissue, and the most consistently reported mechanism is angiogenesis, the growth of new blood vessels into damaged tissue. It up-regulates the VEGFR2 receptor and promotes its internalisation, with downstream signalling through the VEGFR2-Akt-eNOS pathway [4]. It has also been positioned as a brain-gut-axis mediator that modulates serotonergic and dopaminergic systems [7]. Nearly all of that is rodent and cell work. A 2025 review found human data extremely limited, with only three small pilot studies and no rigorous large trial [2].
Is BPC-157 a growth hormone?
No. It is a synthetic fifteen-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice [5], and it is not a hormone of any kind. The confusion has a partial basis: in cultured tendon cells BPC-157 has been reported to increase growth-hormone-receptor signalling, which is one of the routes proposed for its repair effects. Sensitising a receptor is not the same as being the hormone that binds it, and the compound has no approved therapeutic role.
Does BPC-157 damage the liver?
Nothing in the sources gathered here reports liver damage, but the evidence base is far too small to call it safe. The one first-in-human safety pilot infused BPC-157 intravenously at up to 20 mg in two healthy adults and reported no observed adverse events and no measurable change in cardiac, hepatic, renal, thyroid or glucose biomarkers [1]. Two people is not a safety database. A 2025 review concluded that human data are extremely limited and that the compound belongs in the investigational category [2], and unregulated product quality is a separate risk from the molecule itself.
What is semaglutide?
Semaglutide (Ozempic, Wegovy, Rybelsus) is an acylated analogue of human glucagon-like peptide-1. Backbone changes and a fatty di-acid side chain make it resistant to enzymatic breakdown and help it bind reversibly to albumin, so it remains active far longer than native GLP-1. It is an approved prescription medicine available in injected and oral formulations. Naming the brands here identifies the formulations; it is not an endorsement.
What is semaglutide used for?
Approved uses include type 2 diabetes, chronic weight management and reduction of major cardiovascular events in specified populations. The evidence is not one generic weight-loss claim: STEP 1 tested body-weight change [11], SELECT tested cardiovascular outcomes [10], and FLOW tested kidney outcomes in people with type 2 diabetes and chronic kidney disease [9]. Each result belongs to the population and formulation studied. This digest reports those uses and trials without deciding whether the medicine fits any individual.
How does semaglutide work?
It activates the GLP-1 receptor in several tissues at once. In the pancreas it potentiates glucose-dependent insulin secretion and suppresses inappropriate glucagon release. In the stomach it slows gastric emptying. Its weight effect is largely central: it reaches appetite circuits in the hypothalamic arcuate nucleus and the brainstem area postrema, activating the anorexigenic POMC and CART neurons and inhibiting the orexigenic NPY and AgRP neurons, which reduces food intake and shifts food preference without raising energy expenditure. In the STEP 1 trial the weekly injection produced a mean body-weight change of -14.9 percent at week 68 against -2.4 percent on placebo [11].
How does semaglutide work for weight loss?
Its main weight effect is in appetite circuits. GLP-1 receptor activation increases satiety, reduces food intake and changes food preference; slower gastric emptying contributes to fullness and also helps explain nausea. That mechanism is supported by clinical outcomes, not just theory: in STEP 1, the injected formulation produced a mean body-weight change of -14.9 percent at week 68 compared with -2.4 percent on placebo [11]. The result describes that trial, not a guaranteed individual outcome.
What is NAD supplement used for?
NAD+ supplements and their precursors are marketed around ageing, energy metabolism and cellular repair, on the rationale that tissue NAD+ falls with age while enzymes such as the sirtuins, the PARPs and CD38 compete for the remaining pool [16]. The trial evidence supports the biochemical step rather than the destination. Oral nicotinamide riboside at 100 to 1000 mg per day for 8 weeks raised whole-blood NAD+ by 22 percent, 51 percent and 142 percent across the three doses [17], and oral nicotinamide mononucleotide raised it dose-dependently over 60 days [14]. A 2025 review of the human clinical evidence concluded that efficacy in ageing remains limited [13].
Is it safe to take NAD daily?
This site does not advise anyone on what to take or how often. What the trials report is that the precursor studies found no safety issues at the doses tested: nicotinamide riboside at 100 to 1000 mg per day for 8 weeks produced no flushing and no significant difference in adverse events from placebo [17], and a 60-day nicotinamide mononucleotide trial at 300 to 900 mg per day reported no safety issues at any dose [14]. Those are short trials of specific products in specific populations. Separately, supplement purity varies widely without guaranteed third-party testing, and compounded injectable NAD+ has been subject to a Class I recall for elevated bacterial endotoxin.
What is the downside of taking NAD+?
The main downside recorded in this corpus is that the biochemistry works and the clinical case does not yet follow. Blood NAD+ rises on oral precursors [14][17], while the 2025 review of human evidence found limited efficacy, age-related decline consistently observed in only a limited number of human studies, and sparse tissue data [13]. Beyond that: plain oral NAD+ is poorly taken up intact, intravenous NAD+ therapy rests on minimal controlled evidence and can cause chest or abdominal discomfort, flushing and nausea if infused too fast, product quality varies, and a theoretical concern exists that boosting NAD+ could support the metabolism of an existing cancer.
Does NAD cause weight gain?
The composed human studies do not establish NAD+ precursors as a cause of weight gain. One trial of oral nicotinamide mononucleotide reported improved muscle insulin sensitivity but no change in body composition [15]. That is not proof that every NAD+ product is weight-neutral; it is a narrow result from a specific study. Claims about weight loss or weight gain should not be inferred merely from a change in a blood biomarker, and this digest makes neither claim.